[Skip to Content]
[Skip to Content Landing]
Comment & Response
October 2018

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays

Author Affiliations
  • 1Personal Genome Diagnostics, Baltimore, Maryland
JAMA Oncol. 2018;4(10):1430-1431. doi:10.1001/jamaoncol.2018.2323

To the Editor The recent analysis by Torga and Pienta1 attempted to evaluate 2 liquid biopsy test platforms (Guardant360 and PlasmaSELECT) and found “low congruence for the same patient-paired samples.” However, having reanalyzed their available data, we conclude that the authors inappropriately performed a qualitative comparison of 2 quantitative tests with different reporting standards, resulting in a misrepresentation of the underlying data and misleading conclusions. Correcting for these issues, we instead find 91% patient-level concordance between the 2 tests and 100% concordance for results associated with indicated therapies.

×